- Home
- ACVA vs PHAT Comparison
ACVA vs PHAT Comparison
Compare ACVA & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACVA | PHAT |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 894.0M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ACVA | PHAT |
|---|---|---|
| Price | $5.92 | $11.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | $11.32 | ★ $19.83 |
| AVG Volume (30 Days) | ★ 3.7M | 1.3M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.75 | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $759,606,000.00 | $175,110,000.00 |
| Revenue This Year | $14.01 | $93.04 |
| Revenue Next Year | $12.62 | $58.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 19.22 | ★ 216.93 |
| 52 Week Low | $4.07 | $3.92 |
| 52 Week High | $17.16 | $18.31 |
Technical Indicators
Market Signals| Indicator | ACVA | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 43.75 |
| Support Level | $4.86 | $11.04 |
| Resistance Level | $8.37 | $12.83 |
| Average True Range (ATR) | 0.39 | 0.73 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 52.40 | 8.04 |
Price Performance
Historical ComparisonAbout ACVA ACV Auctions Inc.
ACV Auctions Inc operates a mobile platform for wholesale car auctions. It provides a digital marketplace for wholesale vehicle transactions and data services that offer transparent and accurate vehicle information for customers. Additionally, the company's marketplace platform is supported by remarketing centers in various locations throughout the United States.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.